Alliancebernstein L.P. Prelude Therapeutics Inc Transaction History

Alliancebernstein L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $86,000 - $162,325	-21,500 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $13,579 - $26,016	-1,968 Reduced 8.39%	21,500 $148,000
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $116,141 - $310,036	9,768 Added 71.3%	23,468 $292,000
Q3 2021 Nov 10, 2021	SELL	$25.78 - $38.65 $108,276 - $162,330	-4,200 Reduced 23.46%	13,700 $428,000
Q2 2021 Jul 30, 2021	BUY	$28.63 - $44.3 $214,725 - $332,250	7,500 Added 72.12%	17,900 $512,000
Q1 2021 May 06, 2021	BUY	$39.27 - $91.68 $70,686 - $165,024	1,800 Added 20.93%	10,400 $451,000
Q4 2020 Feb 08, 2021	BUY	$28.81 - $88.94 $247,766 - $764,884	8,600 New	8,600 $615,000

30.4M

6.4K

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $29.1M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.